AU2014359456B2 - Sulfoximine substituted quinazolines for pharmaceutical compositions - Google Patents
Sulfoximine substituted quinazolines for pharmaceutical compositions Download PDFInfo
- Publication number
- AU2014359456B2 AU2014359456B2 AU2014359456A AU2014359456A AU2014359456B2 AU 2014359456 B2 AU2014359456 B2 AU 2014359456B2 AU 2014359456 A AU2014359456 A AU 2014359456A AU 2014359456 A AU2014359456 A AU 2014359456A AU 2014359456 B2 AU2014359456 B2 AU 2014359456B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- group
- nov
- hplc
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(CN(*)C1)C1N Chemical compound *C(CN(*)C1)C1N 0.000 description 3
- KAXWNGYTKMIFEU-UHFFFAOYSA-N CC(C)(C)S(C)(=NN)=O Chemical compound CC(C)(C)S(C)(=NN)=O KAXWNGYTKMIFEU-UHFFFAOYSA-N 0.000 description 1
- ZLLXDWGLIIOOJV-HUUCEWRRSA-O CC(C)(C)[SH-](C)(C)O[C@H](CNC1)[C@@H]1Oc(cc(cc1)F)c1[NH+]=O Chemical compound CC(C)(C)[SH-](C)(C)O[C@H](CNC1)[C@@H]1Oc(cc(cc1)F)c1[NH+]=O ZLLXDWGLIIOOJV-HUUCEWRRSA-O 0.000 description 1
- LLQMNZIWXMBAIF-UHFFFAOYSA-N CC(C)S(C)(=NN)=O Chemical compound CC(C)S(C)(=NN)=O LLQMNZIWXMBAIF-UHFFFAOYSA-N 0.000 description 1
- HPUHEMXPHDPUOP-UHFFFAOYSA-N CC(CC1)CS1(=NN)=O Chemical compound CC(CC1)CS1(=NN)=O HPUHEMXPHDPUOP-UHFFFAOYSA-N 0.000 description 1
- GMNOHCLZQFUTNF-NXEZZACHSA-N CC(N(C[C@H]1O)C[C@H]1Oc(nccc1)c1[N+]([O-])=O)=O Chemical compound CC(N(C[C@H]1O)C[C@H]1Oc(nccc1)c1[N+]([O-])=O)=O GMNOHCLZQFUTNF-NXEZZACHSA-N 0.000 description 1
- LDMQKUKYDNRQNR-UHFFFAOYSA-N CCS(C)(=NN)=O Chemical compound CCS(C)(=NN)=O LDMQKUKYDNRQNR-UHFFFAOYSA-N 0.000 description 1
- NFJQHDOIVCXHBB-LICLKQGHSA-N CN(C)/C=N/c1cc(N=S2(CCCC2)=O)cc(Cl)c1C#N Chemical compound CN(C)/C=N/c1cc(N=S2(CCCC2)=O)cc(Cl)c1C#N NFJQHDOIVCXHBB-LICLKQGHSA-N 0.000 description 1
- XBPKEYGZASQSPB-UHFFFAOYSA-N CS(C1CC1)(=N[IH]C)=O Chemical compound CS(C1CC1)(=N[IH]C)=O XBPKEYGZASQSPB-UHFFFAOYSA-N 0.000 description 1
- ITABFAAXBOMMQD-UHFFFAOYSA-N CS(C1CCOCC1)(=NN)=O Chemical compound CS(C1CCOCC1)(=NN)=O ITABFAAXBOMMQD-UHFFFAOYSA-N 0.000 description 1
- NOMWMFNPNMHIGI-YFKPBYRVSA-N CS(N(CC1)C[C@H]1O)(=O)=O Chemical compound CS(N(CC1)C[C@H]1O)(=O)=O NOMWMFNPNMHIGI-YFKPBYRVSA-N 0.000 description 1
- GIXIABVBXXHMKE-UHFFFAOYSA-N CS(c1ccccc1)(=NI)=O Chemical compound CS(c1ccccc1)(=NI)=O GIXIABVBXXHMKE-UHFFFAOYSA-N 0.000 description 1
- PRKGCUXWGSFGJC-UHFFFAOYSA-N CS(c1cccnc1)(=NN)=O Chemical compound CS(c1cccnc1)(=NN)=O PRKGCUXWGSFGJC-UHFFFAOYSA-N 0.000 description 1
- CORJISDKBPDZOO-UHFFFAOYSA-N CS(c1ccncc1)(=NN)=O Chemical compound CS(c1ccncc1)(=NN)=O CORJISDKBPDZOO-UHFFFAOYSA-N 0.000 description 1
- KORXMHTXRZAVHD-UHFFFAOYSA-N NN=S(CC1)(CCC1O)=O Chemical compound NN=S(CC1)(CCC1O)=O KORXMHTXRZAVHD-UHFFFAOYSA-N 0.000 description 1
- COABVVRXKZLELG-UHFFFAOYSA-N NN=S1(CCC1)=O Chemical compound NN=S1(CCC1)=O COABVVRXKZLELG-UHFFFAOYSA-N 0.000 description 1
- OAZANXRGDWCWTO-UHFFFAOYSA-N NN=S1(CCCC1)=O Chemical compound NN=S1(CCCC1)=O OAZANXRGDWCWTO-UHFFFAOYSA-N 0.000 description 1
- YDWPELRKGSOACP-UHFFFAOYSA-N NN=S1(CCCCC1)=O Chemical compound NN=S1(CCCCC1)=O YDWPELRKGSOACP-UHFFFAOYSA-N 0.000 description 1
- MVKJDVGAVWDYTD-UHFFFAOYSA-N Nc1cc2ccc1[o]2 Chemical compound Nc1cc2ccc1[o]2 MVKJDVGAVWDYTD-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N OC(C(F)(F)F)=O Chemical compound OC(C(F)(F)F)=O DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- SIXVGDOMUZZQSK-ZETCQYMHSA-N [O-][N+](c(ccc(Cl)n1)c1O[C@@H](COC1)C1=O)=O Chemical compound [O-][N+](c(ccc(Cl)n1)c1O[C@@H](COC1)C1=O)=O SIXVGDOMUZZQSK-ZETCQYMHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13195720.1 | 2013-12-04 | ||
| EP13195720 | 2013-12-04 | ||
| PCT/EP2014/075890 WO2015082324A1 (en) | 2013-12-04 | 2014-11-28 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014359456A1 AU2014359456A1 (en) | 2016-06-09 |
| AU2014359456B2 true AU2014359456B2 (en) | 2019-01-24 |
Family
ID=49726564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014359456A Ceased AU2014359456B2 (en) | 2013-12-04 | 2014-11-28 | Sulfoximine substituted quinazolines for pharmaceutical compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10093660B2 (enExample) |
| EP (1) | EP3077383B1 (enExample) |
| JP (1) | JP6457523B2 (enExample) |
| AU (1) | AU2014359456B2 (enExample) |
| CA (1) | CA2929742C (enExample) |
| ES (1) | ES2693520T3 (enExample) |
| WO (1) | WO2015082324A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6479854B2 (ja) * | 2014-05-07 | 2019-03-06 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシイミン置換キナゾリン |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| CN112812136B (zh) * | 2019-11-15 | 2022-04-12 | 武汉光谷亚太医药研究院有限公司 | 新型2,3-二氢化茚衍生化合物、制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006136402A1 (en) * | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| WO2007115822A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnkl /mnk2 inhibiting activity for pharmaceutical compositions |
| WO2008141843A1 (en) * | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| WO2011104337A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3987192A (en) | 1974-01-07 | 1976-10-19 | The Upjohn Company | Compositions and process of treatment |
| US5602118A (en) | 1993-03-16 | 1997-02-11 | American Cyanamid Company | 2-thiosubstituted carbapenems |
| CA2188772A1 (en) | 1994-06-08 | 1995-12-14 | Balreddy Kamireddy | Cyclic sulfonamide herbicides |
| SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
| AU2002363175A1 (en) | 2001-10-29 | 2003-05-12 | Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung | Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism |
| MXPA04008403A (es) | 2002-03-01 | 2004-11-26 | Pfizer | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso. |
| GB0315587D0 (en) | 2003-07-03 | 2003-08-13 | Univ Dundee | Anti-inflammatory assay and compounds |
| CN101648906B (zh) | 2004-04-08 | 2012-07-11 | 美国陶氏益农公司 | 杀虫用n-取代亚磺酰亚胺 |
| EP1746099A1 (en) | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
| EP1991547A2 (en) | 2006-03-09 | 2008-11-19 | Pharmacopeia, Inc. | 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders |
| DE602007004618D1 (de) | 2006-06-22 | 2010-03-18 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| JP2011510033A (ja) | 2008-01-25 | 2011-03-31 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | 化合物 |
| WO2011062885A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Fused bicyclic pyrimidine derivatives and methods of use thereof |
| ES2562959T3 (es) | 2010-02-26 | 2016-03-09 | Evotec International Gmbh | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas |
| AR088082A1 (es) | 2011-10-13 | 2014-05-07 | Lilly Co Eli | Moduladores selectivos del receptor androgeno |
| JP6306035B2 (ja) * | 2012-11-09 | 2018-04-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 医薬組成物のためのスルホキシミン置換キナゾリン |
| AU2014301295C1 (en) * | 2013-06-28 | 2018-03-15 | Evotec International Gmbh | Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors |
-
2014
- 2014-11-28 US US15/101,620 patent/US10093660B2/en active Active
- 2014-11-28 CA CA2929742A patent/CA2929742C/en active Active
- 2014-11-28 EP EP14808895.8A patent/EP3077383B1/en active Active
- 2014-11-28 ES ES14808895.8T patent/ES2693520T3/es active Active
- 2014-11-28 JP JP2016536528A patent/JP6457523B2/ja not_active Expired - Fee Related
- 2014-11-28 AU AU2014359456A patent/AU2014359456B2/en not_active Ceased
- 2014-11-28 WO PCT/EP2014/075890 patent/WO2015082324A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006136402A1 (en) * | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
| WO2007115822A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnkl /mnk2 inhibiting activity for pharmaceutical compositions |
| WO2008141843A1 (en) * | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| WO2011104337A1 (en) * | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2693520T3 (es) | 2018-12-12 |
| JP6457523B2 (ja) | 2019-01-23 |
| US20170174668A1 (en) | 2017-06-22 |
| US10093660B2 (en) | 2018-10-09 |
| CA2929742C (en) | 2022-09-20 |
| WO2015082324A1 (en) | 2015-06-11 |
| EP3077383B1 (en) | 2018-08-22 |
| AU2014359456A1 (en) | 2016-06-09 |
| EP3077383A1 (en) | 2016-10-12 |
| CA2929742A1 (en) | 2015-06-11 |
| JP2016539148A (ja) | 2016-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3013805B1 (en) | Sulfoximine substituted quinazolines and their use as mnk1 and/or mnk2 kinase inhibitors | |
| EP2917185B1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| EP2539346B1 (en) | 4-[heterocycloalkyloxy(hetero)arylamino] thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions | |
| EP2539344A1 (en) | Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions | |
| EP3077383B1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| WO2015091156A1 (en) | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions | |
| AU2015257917C1 (en) | Sulfoximine substituted quinazolines for pharmaceutical compositions | |
| CN121816347A (zh) | 药物化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |